Medical management of ulcerative colitis by Rogler, G
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Treatment Algorithms in IBD (1) 
 Dig Dis 2009;27:542–549 
 DOI: 10.1159/000233295 
 Medical Management of Ulcerative Colitis 
 Gerhard Rogler 
 Division of Gastroenterology and Hepatology, Department of Visceral Medicine, University Hospital Zürich, 
 Zürich , Switzerland 
 Introduction 
 Ulcerative colitis (UC) besides Crohn’s disease is the 
most important chronic inflammatory bowel disease. Its 
incidence in Europe is estimated to be 5–25 new patients 
per 100,000 inhabitants per year  [1–5] . As its course and 
extent vary considerably, an individualized diagnostic 
approach and therapy are mandatory.
 Clearly the therapeutic management of UC is focused 
on the induction and maintenance of remission. How-
ever, presently we face a discussion of whether clinical or 
endoscopical remission should be the final treatment 
goal. During relapses or flares of UC, pharmacological or 
surgical interventions are needed to re-establish remis-
sion. For the re-establishment of remission and achieve-
ment of long-term remission, strategies have to be em-
ployed that minimize steroid use and therapy-related side 
effects.
 Treatment decisions are based on disease severity, i.e. 
mild, moderate or severe. The degree of inflammation is 
a crucial factor for the choice of the therapeutic proce-
dures. In addition, the duration of the symptoms, preced-
ing therapy/therapies, disease history as well as individ-
ual symptoms influence the therapy decision. The extent 
of the disease (pancolitis, left-sided colitis, rectosigmoid-
itis or proctitis) will clearly be of impact on the decision 
for a specific therapy. Symptoms indicating the severity 
of the disease flare – such as vomiting, signs of bowel 
 obstruction, number of bowel movements, presence of 
blood, weight loss, high fever and abdominal tenderness 
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 Abstract 
 Ulcerative colitis (UC) is a chronic and relapsing inflamma-
tion limited to the colonic mucosa and always involving the 
rectum with variable extension towards the cecum. The aim 
of medical treatment is to induce and maintain clinical re-
mission. In contrast to Crohn’s disease for which a ‘top-down’ 
or ‘early aggressive’ therapy is discussed, in UC the concept 
of a step-up treatment is still valid. This step-up approach 
includes local or systemic administration of 5-aminosalicylic 
acid as first-line therapy followed by topical or systemic ste-
roid administration as well as azathioprine, 6-mercaptopu-
rine, cyclosporine, and more recently anti-tumor necrosis 
factor monoclonal antibodies as options in refractory or 
chronic active disease. Colectomy may be necessary if med-
ical treatments are unsuccessful or if complications develop. 
The decision about the individual therapy of UC is depen-
dent on both disease activity and on disease location. Dif-
ferent therapy strategies are applied in ulcerative proctitis, 
left-sided colitis, pancolitis and fulminant colitis as well as in 
chronic active disease and maintenance of remission. This 
overview presents important concepts in the treatment of 
UC based on the published guidelines. 
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and pain during defecation – are useful practical criteria 
of severity in everyday medical practice. Frequently, the 
efficacy of a topical local therapy is underestimated, or is 
not addressed, because of the rectal application.
 The valid guidelines represent the basis on which the 
optimal therapy must be determined for the individual 
patient.
 Medical Management of Acute Flares of Ulcerative 
Colitis 
 An acute flare of UC is usually characterized by typi-
cal clinical complaints, such as frequent bowel move-
ments, bloody diarrhea and abdominal pain. It is fre-
quently recommended to exclude an infectious colitis be-
fore starting any treatment. The impact and efficacy of 
such ‘routine diagnostics’, however, has never been really 
evaluated. A recent development is an increase in the in-
cidence of  Clostridium difficile colitis and CMV colitis 
among UC patients, especially under immunosuppres-
sive conditions. This has to be kept in mind in patients 
that seem to have steroid-refractory UC.
 The choice of therapy for acute flares or relapses of UC 
is based on the clinical presentation. The value of labora-
tory markers for the therapy decision is limited. As a 
minimum requirement, hemoglobin levels, leukocyte 
counts as well as general inflammation parameters such 
as thrombocyte counts, ESR or CRP should be deter-
mined  [6] . ‘Control colonoscopies’ without therapeutic or 
prognostic consequences are not indicated and should 
not be performed during an acute flare of UC. Changes 
in the extension of the disease can also be proven by ul-
trasound in the hands of an experienced doctor.
 In general, a step-up approach is recommended in all 
guidelines for the treatment of UC ( fig. 1 ). An abundance 
of evidence exists that supports the use of aminosalicy-
lates (5-ASA) in mild to moderate UC for the induction 
of remission. Corticosteroids are used in patients not re-
sponding to 5-ASA or in patients with more severe dis-
ease. Azathioprine (AZA) and 6-mercaptopurine (6-MP) 
have been shown to be useful in steroid-refractory pa-
tients.
 Left-Sided Colitis, Rectosigmoiditis, Proctitis 
 Distal or left-sided UC with mild to moderate activity 
should be initially treated topically  [7] . The rectal appli-
cation of steroids (as enema or foam) is superior to pla-
cebo; however, 5-aminosalicylic acid (5-ASA) is superior 
to steroids in topical application  [8, 9] . Consecutively, 
treatment of first choice in mild to moderate left-sided 
colitis or rectosigmoiditis are foams or enemas with 5-
ASA (mesalamine)  [7, 10] . During an acute flare of colitis, 
application of enemas is frequently uncomfortable due to 
the at times large volume (up to 100 ml), making them 
less well tolerated by the patients  [11] . In patients with 
UC, the rectum is usually the side of the most severe in-
flammation. It contains the highest number of sensory 
nerves in the bowel. Therefore, it is easily conceivable that 
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 Fig. 1. Step-up therapy approach in UC. 
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 Fig. 2. Advantage of combination therapy of oral and rectal 5-
ASA therapy over monotherapy (according to Safdi et al. [12]). 
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such a large volume of fluid will cause complaints. Foams 
are better accepted by the patients in general (potentially 
also due to the smaller volume). In ulcerative proctitis, 5-
ASA suppositories should be used  [11] . 
 If the disease extends to the left colonic flexure, it ap-
pears to be recommendable to combine topical therapy 
with an oral 5-ASA preparation  [12–14] . The recom-
mended duration of treatment is at least 4 weeks  [10, 15] . 
The minimal, but sufficient topical dose for the achieve-
ment of a remission is 1 g 5-ASA per day  [14] . Higher 
doses up to 4 g/day have not been proven to be more ef-
fective  [10, 15, 16] . If a topical therapy with 5-ASA over 
several weeks is ineffective, topical steroids should be 
added for at least 4 weeks  [17, 18] . If the topical therapy 
finally fails, systemic steroids should be used  [13, 19] . A 
severe flare of a distal colitis should primarily be treated 
orally with systemic steroids, if possible in combination 
with topical use of 5-ASA  [13, 20] ( fig. 2 ).
 In different studies, initial steroid doses between 40 
and 60 mg/day did not seem to exhibit remarkable differ-
ences in therapeutic efficacy  [21] .
 Pancolitis 
 A mild to moderate flare of a pancolitis should ini-
tially be treated with oral 5-ASA  [16, 22, 23] ( fig. 3 ). 4 g 
5-ASA per day are superior to 2 g. Usually it has been rec-
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 Fig. 3.  Treatment algorithm for mild to 
moderate UC. 
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 Fig. 4. Treatment algorithm for moderate 
to severe UC. 
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ommended that 5-ASA should be taken in three doses 
over the day. Newer studies from the last years indicate 
that the total daily dose can be taken at one time (e.g. in 
the morning) – or even should be taken at one time, as in 
some studies there was even increased efficacy under 
these conditions  [24–26] . The possibility to take the whole 
dose at one time is also likely to increase patient compli-
ance and adherence to therapy. From several studies we 
know that the main drawback of 5-ASA therapy (and 
probably the most important reason for therapy failure) 
is a reduced adherence due to the mode of intake and the 
number of tablets or capsules (up to 8 per day). With re-
spect to this, new formulations as ‘granules’ or ‘sachets’ 
may also be of clear advantage.
 During severe pancolitis or lack of response to a ther-
apy with 5-ASA, systemic glucocorticoids should be used 
orally or intravenously (initially a 60-mg prednisone 
equivalent per day)  [27, 28] ( fig. 4 ). In patients requiring 
steroid therapy, the immediate outcomes are favorable, 
but the long-term outcome at 1 year is somewhat disap-
pointing. About half of the patients with UC initially 
treated with steroids will require additional therapy after 
1 year. A population-based study has shown that a year 
after the initial course of corticosteroid treatment, a pro-
longed steroid response is seen in only 49% of patients 
with UC. However, sometimes a second course of steroid 
therapy will induce remission again. In addition, num-
bers may change with sufficient and well-adhered main-
tenance therapy. Steroid dependence has been reported 
to develop in 22% of UC patients, with surgery being re-
quired in 29% of those patients. In general, a state of ste-
roid dependence should clearly be avoided. Therefore, it 
is questionable whether this really can be a measure in 
clinical studies. Whether the steroids for pancolitis are 
given orally or intravenously should be decided with re-
spect to the clinical presentation of the patient.
 Usually steroids are combined with oral aminosalicy-
lates, although the efficacy or advantage of such a combi-
nation has never been documented by appropriate clini-
cal studies. The tapering of steroids has long been per-
formed very schematically. Tapering regimes differing 
from country to country have been established. In the 
meantime it is accepted that tapering of steroids should 
be planned individually according to the patient’s clinical 
symptoms. If no response can be achieved by the oral ad-
ministration of steroids, a change to one course of intra-
venous administration is usually recommended. This 
could be justified with the assumption that during severe 
colitis there is increased peristalsis also of the small bow-
el and resorption of oral steroids could be reduced. Stud-
ies on the change of an oral steroid administration to an 
intravenous one do not exist; however, in the experience 
of most clinicians this approach has clinically worked for 
a number of patients. An intravenous therapy duration of 
10 days is generally sufficient. If no improvement is ob-
served within a period of 10 days, therapy has to be re-
considered and changed. Before the infliximab era, cy-
closporine at a dose of 4 mg/kg  day i.v. was primarily
recommended  [28] . The Leuven group has shown that 
cyclosporine 2 mg/kg  day i.v. is equivalently effective 
 [29] . Serum levels can be measured at any time during 
therapy, since by the continuous infusion steady-state 
levels are reached early. The ACT-1 and ACT-2 studies 
among others showed that the anti-tumor necrosis factor 
antibody infliximab (5 mg/kg in weeks 0, 2 and 8 and 
then every 8 weeks) is effective in severe UC  [30–32] . The 
discussion at which time point in the step-up approach of 
severe UC treatment infliximab should be used is still 
ongoing  [33] . New data also exist for a successful therapy 
with tacrolimus in this situation  [34, 35] . Tacrolimus can 
be used in individual cases as an alternative to cyclospo-
rine.
 Medical Management of Severe Acute Colitis/Toxic 
Megacolon 
 A severe flare is characterized by the respective clini-
cal symptoms which include systemic signs such as fever, 
tachycardia and anemia as well as increased inflamma-
tion parameters. Crucial symptoms are frequent bloody 
diarrhea, fever  1 38.5 ° C and weight loss. An abdominal 
X-ray should be performed to search for a dilation of the 
colon (toxic megacolon)  [36] .
 A megacolon is present if the diameter of the colon 
transversum is  1 5.5 cm. Ultrasound can be a useful di-
agnostic supplement in this situation  [36] . A sigmoidos-
copy may be useful to exclude  C. difficile colitis and CMV 
colitis. Since a fulminant colitis or a toxic megacolon can 
also occur on the basis of an intestinal infection, investi-
gations on  C. difficile toxin as well as an adequate CMV 
diagnostic (e.g. immunohistochemistry for pp65) should 
be performed  [37–39] . For the treatment of a fulminant 
flare of UC, the patient should be hospitalized. An inter-
disciplinary approach between gastroenterologists and 
visceral surgeons is mandatory. A conservative therapy 
should only be performed if no contraindications exist 
 [40] .
 Treatment can be started with a course of intravenous 
steroids, e.g. 4  ! 100 mg hydrocortisone per day  [41] . In 
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addition to fluid and electrolyte substitution, parenteral 
nutrition may be indicated. If steroid therapy fails (no 
sufficient treatment response within 3–5 days) and a clear 
indication for surgery is not given, a therapy with intra-
venous cyclosporine (2 or 4 mg/kg  day as continuous in-
fusion) may be applied  [28, 42, 43] . As mentioned, in-
fliximab has been proven to be an alternative in this sit-
uation in several studies  [31, 44–46] .
 If intravenous cyclosporine is successful after 7–10 
days, it is usually switched to oral therapy for mainte-
nance of remission and combined with other immuno-
suppressants such as AZA (2.5 mg/kg  day)  [43] . Oral cy-
closporine cannot be expected to maintain remission for 
longer periods. Approximately 60–80% of the patients 
benefit on a long-term basis and for 40% of the patients 
colectomy can be avoided  [43] . As an alternative to cyclo-
sporine, tacrolimus has also been successfully used  [34, 
47] . This therapy should be reserved to centers with ap-
propriate experience.
 If the need for a rapid surgical intervention is possible, 
further corticosteroids should be avoided as steroids in-
crease the risk of post-surgical (infectious) complications 
 [48] . Parenteral nutrition should applied for fluid and 
electrolyte substitution. In controlled studies, however, 
this was not superior to enteral nutrition. Clearly, enter -
al nutrition cannot be used under subileus/ileus condi -
tions. Controlled studies do not show an advantage of an 
additional administration of antibiotics; therefore, this 
should only be done if signs of infection/superinfection 
or peritonitis are present.
 After achieving remission, AZA (2–2.5 mg/kg) can be 
used for maintenance therapy  [49, 50] . A  Pneumocystis 
carinei/jiroveci prophylaxis is recommended during the 
triple immunosuppression (cyclosporine, AZA and sys-
temic steroids). The efficacy of such prophylaxis has not 
been proven so far  [51] . If therapy fails, early colectomy 
should be performed. The clinical value of leukocyte 
apheresis is still a matter of discussion.
 Medical Management of Chronic Active Ulcerative 
Colitis 
 A chronic active disease is characterized by the persis-
tence of clinical symptoms (diarrhea, blood loss, pain) 
despite an adequate medical therapy. Also, a disease 
course that has shown some improvement upon therapy 
which is however not complete and permanent ( ! 2 re-
lapses/year) is termed a  chronic active disease . A colonos-
copy with biopsies and subsequent histology may be help-
ful in individual cases, e.g. for the exclusion of CMV coli-
tis. In cases of severe, chronically active UC, the option 
of a colectomy should always be discussed with the pa-
tient.
 If no colectomy is performed for the moment, an im-
munosuppression with AZA/6-MP may be useful  [52, 
53] . Newer studies indicate that infliximab can also be 
given if a fast therapy response is desired or necessary 
 [32] . In individual cases the discrimination of a chroni-
cally active colitis and irritable bowel syndrome can be 
difficult. Particularly in therapy-refractory disease under 
immunosuppression, an appropriate diagnostic proce-
dure must be undertaken to exclude CMV colitis. Oral 
systemic steroids should not be used as continuous ther-
apy due to their side effects. In chronically active distal 
colitis, however, the long-term rectal administration of 
steroid enemas or foams may be acceptable due to their 
low systemic bioavailability. 
 A therapy failure on AZA therapy can at the earliest 
be diagnosed after 6 months of continuous administra-
tion. Maintenance therapy with AZA or 6-MP should be 
applied for 3–5 years  [54, 55] . According to all available 
data, the administration of AZA during pregnancy is re-
garded as being safe. Upon administration of AZA/6-MP 
the leukocyte count and the transaminases must be con-
trolled regularly if abdominal pain occurs. Additionally, 
serum lipase levels should be determined. After start of 
the immunosuppressive therapy, leukocyte counts and 
GPT values should be controlled after 1, 2, 4, 8 and 12 
weeks, thereafter at least every 12 weeks. Upon AZA ther-
apy, bone marrow suppression may occur, which must be 
discovered in time. With leukocyte numbers  ! 2,500, 
AZA therapy should be terminated. After normalization 
of the values a therapy may be restarted with lower doses 
(e.g. 50 mg/day) under close supervision. Pancreatitis 
may occur usually in the first weeks of treatment and re-
quire immediate termination therapy. Minor increases in 
serum lipase or amylase without clinical symptoms are 
frequently observed in inflammatory bowel disease pa-
tients; their relevance remains obscure, an observing at-
titude is acceptable. A subsequent rise of serum liver en-
zymes under therapy is also a reason for termination of 
AZA/6-MP therapy.
 The use of infliximab represents an important thera -
py alternative  [32] . It is regarded to be safe and well toler-
ated, however, a tuberculosis skin test or lymphocyte 
stimulation test (such as QuantiFERON  ) as well as a 
lung X-ray need to be performed prior to starting the 
therapy. It needs to be kept in mind that tuberculosis 
screening can be false-negative due to immunosuppres-
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sion. Only 22% of patients will be in remission without 
the need of additional steroids according to the ACT-1 
and ACT-2 data. On the other hand, treatment success is 
usually rapid and an improvement of the patients can be 
observed sometimes already on the day after the admin-
istration.
 The administration of methotrexate can be considered 
in individual cases in adult patients but also in children 
 [56] . The initial dose is 20–25 mg parenterally (oral, i.m., 
s.c.) every week (children: 15 mg/m 2 body surface). After 
achieving remission, a dose reduction to 10–15 mg/week 
is usually recommended. Regular blood cell counts must 
also take place under a therapy with methotrexate. For 
the monitoring of the potential hepatotoxicity, regular 
measurements of liver enzymes should be performed. 
Preexisting chronic liver disease or chronic lung disease 
represent contraindications for the therapy. The oral ad-
ministration of tacrolimus (0.1–0.2 mg/kg b.w.) and the 
use of a leukocyte apheresis can be considered in indi-
vidual cases.
 Maintenance of Remission in Ulcerative Colitis 
 The definition of remission is based on clinical fea-
tures. Criteria for remission are absence of diarrhea ( 1 3 
bowel movements/day), no visible blood in stools as well 
as no UC-associated intestinal or extraintestinal com-
plaints. For maintenance of remission in patients with 
UC, first-line therapy is 5-ASA administered orally or 
rectally  [57–59] . The combination of oral and rectal/top-
ical therapy is superior to oral monotherapy ( fig. 2 ). In 
the case of distal UC, evidence for the superiority of the 
rectal application exists  [59] .
 The compliance or adherence on maintenance therapy 
is crucial for its success  [60] . If more than two-thirds of 
the recommended dose is taken, the risk of a flare or re-
lapse in the first year is only approximately 10–20%  [61] . 
With respect to this, it is certainly favorable that newer 
studies point to the fact that the entire 5-ASA dosage can 
be taken at one time (e.g. either the morning or evening), 
i.e., the distribution into three doses is no longer neces-
sary.
 The effectiveness of the following minimal dosages 
has been demonstrated in clinical studies: (1)  oral admin-
istration: SASP 2 g/day; 5-ASA 1.5 g/day; olsalazine 1.0 
g/day, (2)  rectal administration: left-sided colitis: 5-ASA 
enemas either 1 g/day or 4 g each third day or 4 g/day on 
the first 7 days of the month; proctitis: 5-ASA supposito-
ries 2  ! 500 mg/day or 1 g/day three times weekly.
 Since individual patients prefer mesalazine foams as 
compared to enemas, this form of application can prob-
ably be given at a similar dosage, even if studies are not 
available for maintenance of remission with foam prepa-
rations. Maintenance therapy should be administrated 
for at least 2 years. 
 Upon incompatibility of 5-ASA, a probiotic pathogen 
preparation, e.g.  Escherichia coli Nissle, can be used suc-
cessfully for the maintenance of remission with a similar 
clinical efficacy  [62, 63] . As alternatives for complicated 
UC, AZA/6-MP  [53] and infliximab can be used for the 
maintenance of remission  [32] . Systemic steroids should 
not be used for maintenance therapy. The increased ef-
ficacy of a combination of oral and rectal therapy with 
5-ASA is well documented by clinical studies; however, 
most patients prefer monotherapy.
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